Medifast Announces Cooperation Agreement with Steamboat Capital Mar 20, 2026 8:30 AM Eastern Daylight Time Medifast Announces Cooperation Agreement with Steamboat Capital Share Company Agrees to Nominate Parsa Kiai and Jeff Rose as Director Candidates at 2026 Annual Meeting of Stockholders "We are pleased to have reached this agreement through a constructive and collaborative dialogue with the Medifast Board and management team," said Parsa Kiai Managing Partner and Chief Investment Officer at Steamboat Cap ...

Core Viewpoint - Medifast's recent earnings report indicates a significant decline in both revenue and earnings, raising concerns about the company's future performance and market position [2][3][4]. Financial Performance - Medifast reported a fourth-quarter loss of $1.65 per share, which was wider than the Zacks Consensus Estimate of a loss of 76 cents per share [3]. - Net revenues for the quarter were $75.1 million, reflecting a year-over-year decline of 36.9%, although it exceeded the Zacks Consensus Estimate of $70.8 million [4]. - The average revenue per active earning OPTAVIA Coach increased by 6.2% year over year to $4,664, despite the overall revenue decline [4]. Operational Challenges - The total number of active earning OPTAVIA coaches decreased by 40.6% year over year to 16,100, attributed to client acquisition challenges and increased competition from GLP-1 medications in the weight-loss market [5]. - Gross profit fell to $52.1 million, down 40.9% year over year, with a gross margin of 69.4%, compared to 74.1% in the prior year [6]. Cost Management - Selling, general, and administrative expenses decreased by 31.5% year over year to $59.9 million, primarily due to lower sales volumes and fewer active coaches [7]. - Despite the decline in absolute terms, SG&A expenses rose to 79.8% of revenue, reflecting reduced fixed-cost leverage and higher event and restructuring costs [8]. Financial Health - As of December 31, 2025, Medifast had cash, cash equivalents, and investment securities totaling $167.3 million, with no debt and total shareholders' equity of $198.9 million [9]. Future Outlook - For the first quarter of 2026, Medifast expects revenues between $65 million and $80 million, with a loss per share projected between 15 cents and 70 cents [11]. - For the full year 2026, revenues are anticipated to range from $270 million to $300 million, with a loss per share expected between $1.55 and $2.75 [11]. Market Sentiment - Following the earnings release, there has been a downward trend in estimates, with the consensus estimate shifting by -358.33% [12]. - Medifast currently holds a Zacks Rank of 4 (Sell), indicating expectations of below-average returns in the coming months [14].

BALTIMORE--(BUSINESS WIRE)--As part of its continued focus on improving metabolic health, Medifast® (NYSE: MED) today announced that OPTAVIA's comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). OPTAVIA clients may be able to save up to 40% on program costs by working with their medical provider and insurance administrator to use pre-tax medical funds, offering accessibility for. ...

Core Insights - Medifast, Inc. (MED) reported fourth-quarter 2025 results with revenues exceeding estimates but a wider-than-expected loss per share, indicating challenges in the business [1][10]. Financial Performance - The company reported a quarterly loss of $1.65 per share, which was significantly worse than the Zacks Consensus Estimate of a loss of 76 cents per share. This loss included a tax provision charge of $12.1 million, equating to a loss of $1.10 per share [2]. - Net revenues were $75.1 million, reflecting a 36.9% decline year over year, primarily due to a decrease in the number of active earning OPTAVIA coaches. However, this figure surpassed the Zacks Consensus Estimate of $70.8 million [3][10]. - The average revenue per active earning OPTAVIA Coach increased by 6.2% year over year, rising to $4,664 from $4,391, indicating improved productivity among the remaining coaches [3]. Operational Challenges - The total number of active earning OPTAVIA coaches fell by 40.6% year over year to 16,100 from 27,100, attributed to difficulties in client acquisition and increased competition from GLP-1 medications in the weight-loss market [4]. - Gross profit decreased by 40.9% year over year to $52.1 million, with a gross margin of 69.4%, down from 74.1% in the previous year. This decline was due to a loss of fixed cost leverage and a one-time restructuring charge [5]. Cost Management - Selling, general, and administrative (SG&A) expenses decreased by 31.5% year over year to $59.9 million, driven by a reduction in coach compensation and marketing expenses. However, SG&A as a percentage of revenue increased to 79.8% due to fixed-cost leverage loss and higher event costs [6][7]. Financial Health - As of December 31, 2025, Medifast had cash, cash equivalents, and investment securities totaling $167.3 million, with no debt and total shareholders' equity of $198.9 million, indicating a stable financial position despite operational losses [8]. 2026 Outlook - For 2026, Medifast projects revenues between $270 million and $300 million, with an anticipated loss per share ranging from $1.55 to $2.75. The first-quarter 2026 revenue is expected to be between $65 million and $80 million, with a loss per share between 15 cents and 70 cents [10][11].

Core Insights - The company is transitioning from a weight loss focus to a broader metabolic health approach, termed "Metabolic Synchronization," in response to industry disruptions and changing consumer expectations [2][5][21] Financial Performance - Medifast reported a fourth-quarter revenue decline of 36.9% to $75.1 million, with a net loss of $18.1 million, influenced by a $12.1 million non-cash valuation allowance [4][10][12] - The company ended 2025 with $167.3 million in cash and no debt, and it reinstated 2026 revenue guidance of $270 million to $300 million, anticipating profitability improvements starting in Q4 2026 [4][16] Coach Productivity and Engagement - Despite a 40.6% decline in active earning coaches to approximately 16,100, average revenue per active coach increased by 6.2% to $4,664, indicating early signs of improved coach productivity [5][11] - Initiatives to enhance coach productivity include higher levels of coach-led opportunity meetings and training activities, with a notable percentage of coaches reaching executive director rank [6][7] Leadership Transition - CEO Dan Chard will step down on June 1, 2026, with President Nick Johnson expected to take over, while Chard will remain as chairman [2][5] Market Dynamics - The company is adapting to the impact of GLP-1 medications on the weight loss industry, with a focus on clients who may seek alternatives after discontinuing these medications [10][20] - Medifast's messaging around visceral fat reduction and lean mass preservation is resonating with consumers focused on body composition [20]

分组1 - Medifast reported a quarterly loss of $0.55 per share, better than the Zacks Consensus Estimate of a loss of $0.76, representing an earnings surprise of +27.63% [1] - The company posted revenues of $75.1 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 6.05%, but down from $119 million year-over-year [2] - Medifast has surpassed consensus EPS estimates two times and revenue estimates three times over the last four quarters [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - Medifast shares have increased by about 0.8% since the beginning of the year, while the S&P 500 has declined by 0.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.12 on revenues of $67.12 million, and -$0.57 on revenues of $228.38 million for the current fiscal year [7] 分组3 - The Zacks Industry Rank indicates that the Food - Miscellaneous sector is in the bottom 16% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5][6] - Medifast currently holds a Zacks Rank 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Financial Data and Key Metrics Changes - Fourth quarter 2025 revenue was $75.1 million, a decrease of 36.9% year-over-year, primarily due to a decrease in the number of active earning coaches [25] - Loss per share for the fourth quarter was $1.65, impacted by a $12.1 million non-cash valuation allowance against deferred tax assets, which represented $1.10 of the loss per share [24][31] - Revenue per active earning coach reached $4,664, a year-over-year increase of 6.2%, marking the first year-over-year growth since Q2 2022 [25][26] Business Line Data and Key Metrics Changes - The number of active earning coaches decreased by 40.6% year-over-year, ending the quarter with approximately 16,100 coaches [25] - Coach productivity turned positive year-over-year for the first time since mid-2022, increasing by 6% in the fourth quarter [11] Market Data and Key Metrics Changes - The rapid adoption of GLP-1 medications continues to impact the traditional weight loss category, influencing the company's restructuring efforts [25] - A national survey indicated that nearly 94% of American adults express concern about at least one aspect of metabolic health, highlighting a large underserved market [8] Company Strategy and Development Direction - The company is transitioning to focus on metabolic health rather than solely weight loss, emphasizing a scientific approach called Metabolic Synchronization [6][10] - A new product line is being developed to support metabolic health, aiming to reduce harmful visceral fat and improve overall health [9][10] - The company is committed to disciplined execution to regain profitability while maintaining financial flexibility for growth investments [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the direction of the company and the strength of the leadership team, indicating that early indicators show progress in coach productivity and business performance [10][22] - The company expects to see continued coach productivity growth in the first quarter of 2026, with annual revenue guidance set between $270 million and $300 million [33] Other Important Information - The company ended the year with $167.3 million in cash and no debt, indicating a strong balance sheet [32] - A restructuring initiative was executed across all business functions, targeting future savings of over $30 million [28] Q&A Session Summary Question: Insights on coach productivity and consumer demographics - Management noted that the improvement in coach productivity reflects a new focus on metabolic health, attracting a different type of customer seeking health benefits beyond weight loss [37][39] Question: Revenue expectations for 2026 - Management indicated that while they are not providing quarterly guidance, they expect stabilization and gradual improvement in revenue throughout the year, with potential for positive growth by Q4 [41][43] Question: Alignment of new product innovations with consumer needs - Management highlighted that there is a growing inflow of clients transitioning off GLP-1 drugs, which aligns with the company's new product offerings aimed at addressing these consumers' needs [45][46]

Financial Data and Key Metrics Changes - Fourth quarter 2025 revenue was $75.1 million, a decrease of 36.9% year-over-year, primarily due to a decrease in the number of active earning coaches [25] - Loss per share for the fourth quarter was $1.65, impacted by a $12.1 million non-cash valuation allowance against deferred tax assets, which represented $1.10 of the loss per share [24][31] - Revenue per active earning coach reached $4,664, a year-over-year increase of 6.2%, marking the first year-over-year growth since Q2 2022 [25][26] Business Line Data and Key Metrics Changes - The number of active earning coaches decreased by 40.6% year-over-year, ending the quarter with approximately 16,100 coaches [25] - Coach productivity turned positive year-over-year for the first time since mid-2022, increasing by 6% in the fourth quarter [11] Market Data and Key Metrics Changes - The rapid adoption of GLP-1 medications continues to impact the traditional weight loss category, influencing the company's restructuring efforts [25] - A national survey indicated that nearly 94% of American adults express concern about at least one aspect of metabolic health, highlighting a large underserved market [8] Company Strategy and Development Direction - The company is transitioning to focus on metabolic health rather than solely weight loss, emphasizing a scientific approach called Metabolic Synchronization [6][10] - A new product line is being developed to support metabolic health, aiming to reduce harmful visceral fat and improve overall health [9][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the direction of the company and the strength of the leadership team, indicating a shift from transformation to execution [10][22] - The company expects to see continued coach productivity growth and is targeting improvements in profitability starting in Q4 2026 [33] Other Important Information - The company executed a restructuring across all business functions, targeting future savings of over $30 million [28] - The balance sheet remains strong, with $167.3 million in cash and no debt as of December 31, 2025 [32] Q&A Session Summary Question: Insights on coach productivity and consumer demographics - Management noted that the improvement in coach productivity reflects a new type of customer focused on metabolic health, with coaches retrained to tell this new story [37][38] Question: Revenue expectations for 2026 - Management indicated that while they are not providing quarterly guidance, they anticipate stabilization in top-line revenue as they move into metabolic health [42][43] Question: Impact of new product innovations on consumer base - Management highlighted a significant inflow of clients transitioning off GLP-1 drugs, which aligns with the company's new product offerings aimed at addressing these consumers' needs [45][46]

Financial Data and Key Metrics Changes - Fourth quarter 2025 revenue was $75.1 million, a decrease of 36.9% year-over-year, primarily due to a decrease in the number of active earning coaches [25] - Loss per share for the fourth quarter was $1.65, impacted by a $12.1 million non-cash valuation allowance against deferred tax assets, which represented $1.10 of the loss per share [24][31] - Revenue per active earning coach reached $4,664, a year-over-year increase of 6.2%, marking the first year-over-year growth since Q2 2022 [25][26] - Gross profit for Q4 2025 decreased 40.9% year-over-year to $52.1 million, with a gross profit margin of 69.4%, down 470 basis points [26] Business Line Data and Key Metrics Changes - The company ended the quarter with approximately 16,100 active earning coaches, a decrease of 40.6% from the fourth quarter of 2024 [25] - Coach productivity turned positive year-over-year for the first time since mid-2022, increasing by 6% in Q4 [12] Market Data and Key Metrics Changes - The rapid adoption of GLP-1 medications continues to impact the traditional weight loss category, contributing to the decline in active earning coaches [25] - A national survey indicated that nearly 94% of American adults express concern about at least one aspect of metabolic health, highlighting a large underserved market [9] Company Strategy and Development Direction - The company is transitioning to a metabolic health focus, emphasizing a scientific approach called Metabolic Synchronization to address metabolic dysfunction rather than just weight loss [6][8] - A new product line is being developed to support metabolic health, aiming to reduce visceral fat and improve body composition [10] - The company is committed to disciplined execution to regain profitability while maintaining financial flexibility for growth investments [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the direction of the company and the strength of the leadership team, indicating that foundational elements for future growth are now in place [11] - Early indicators of improved coach productivity and engagement are seen as signs of potential revenue growth in the future [12][20] - The company expects to see continued coach productivity growth in Q1 2026, with annual revenue guidance set between $270 million and $300 million [33] Other Important Information - The company executed a restructuring across all business functions, targeting future savings of over $30 million [28] - The balance sheet remains strong, with $167.3 million in cash and no debt as of December 31, 2025 [32] Q&A Session Summary Question: Can you provide details on coach productivity and the consumer demographics associated with them? - Management noted that the improvement in coach productivity reflects a new focus on metabolic health, attracting a different type of customer seeking health benefits beyond weight loss [36][38] Question: How do you see revenue trends progressing through 2026? - Management indicated that while they are not providing quarterly guidance, they expect stabilization and gradual improvement in revenue throughout the year, with a focus on the transition to metabolic health [41][43] Question: What insights can you share about the new product lineup and its alignment with consumer needs? - Management highlighted that there is a growing inflow of clients transitioning off GLP-1 drugs, which the company is well-positioned to attract with its new offerings [44][46]